News stories about Quanterix (NASDAQ:QTRX) have been trending somewhat positive on Thursday, according to Accern. The research group identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Quanterix earned a daily sentiment score of 0.02 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.7715184989344 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Quanterix Corp (QTRX) Receives Average Rating of “Strong Buy” from Brokerages (americanbankingnews.com)
- Quanterix (QTRX) Upgraded by ValuEngine to “Hold” (americanbankingnews.com)
- Quanterix (QTRX) Now Covered by Leerink Swann (americanbankingnews.com)
- Quanterix (QTRX) Receives New Coverage from Analysts at BTIG Research (americanbankingnews.com)
- Quanterix (QTRX) Now Covered by Cowen (americanbankingnews.com)
Several analysts have issued reports on the company. ValuEngine upgraded Quanterix from a “sell” rating to a “hold” rating in a research note on Monday. JPMorgan Chase assumed coverage on Quanterix in a research note on Tuesday, January 2nd. They set an “overweight” rating on the stock. Leerink Swann assumed coverage on Quanterix in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $27.00 price objective on the stock. Cowen assumed coverage on Quanterix in a research note on Tuesday, January 2nd. They set an “outperform” rating on the stock. Finally, BTIG Research assumed coverage on Quanterix in a research note on Tuesday, January 2nd. They set a “buy” rating and a $26.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Quanterix presently has a consensus rating of “Buy” and a consensus price target of $26.50.
COPYRIGHT VIOLATION NOTICE: “Quanterix (NASDAQ:QTRX) Earns Media Impact Rating of 0.02” was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://baseballnewssource.com/2018/04/05/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-quanterix-qtrx-stock-price/2028514.html.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and SR-X system that supports the detection capability of approximately six biomarkers per test.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.